Loading publications…
The last 5 uploaded publications
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, P. Abada, Masatoshi Kudo (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), pp. 282-296, DOI: 10.1016/s1470-2045(18)30937-9.
Article145 days agoREACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Ho Yeong Lim, Marc Pracht, Kun‐Ming Rau, Philippe Merle, Kenta Motomura, Izumi Ohno, Bruno Daniele, Dongbok Shin, Guido Gerken, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo (2018). REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. Journal of Clinical Oncology, 36(15_suppl), pp. 4003-4003, DOI: 10.1200/jco.2018.36.15_suppl.4003.
Article145 days agoRamucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun‐Ming Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu (2021). Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 10(5), pp. 451-460, DOI: 10.1159/000516605.
Article145 days agoRamucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
Richard S. Finn, Masatoshi Kudo, Yoon‐Koo Kang, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Ho Yeong Lim, Marc Pracht, Kun Ming Rau, Philippe Merle, Kenta Motomura, Izumi Ohno, Bruno Daniele, Dongbok Shin, Guido Gerken, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu (2019). Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.. Journal of Clinical Oncology, 37(4_suppl), pp. 326-326, DOI: 10.1200/jco.2019.37.4_suppl.326.
Article145 days agoRamucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
Josep M. Llovet, Chia‐Jui Yen, Richard S. Finn, Yoon‐Koo Kang, Masatoshi Kudo, Peter R. Galle, Éric Assenat, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Christophe Borg, Jean‐Baptiste Hiriart, Bruno Daniele, Thomas Berg, Hyun Cheol Chung, N Godinot, Chunxiao Wang, Yanzhi Hsu, William R. Schelman, Andrew X. Zhu (2019). Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).. Journal of Clinical Oncology, 37(15_suppl), pp. 4073-4073, DOI: 10.1200/jco.2019.37.15_suppl.4073.
Article145 days ago